EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Beyond blood: Advancing the frontiers of liquid biopsy in oncology and personalized medicine

Ying Bao, Dejing Zhang, Huihui Guo, Wenxue Ma iD

Cancer Science · 2024-04 · 115 (4) · 1060-1072

DOI: 10.1111/cas.16097 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Science, online erschienen am 03.02.2024. Verfasst von Ying Bao und 3 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory for Translational Medicine, The First Hospital Affiliated with Huzhou University, Huzhou, China. Hauptthemen laut MEDLINE: Circulating Tumor DNA, Neoplastic Cells, Circulating. Die Arbeit wurde bisher 114-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Liquid biopsy is emerging as a pivotal tool in precision oncology, offering a noninvasive and comprehensive approach to cancer diagnostics and management. By harnessing biofluids such as blood, urine, saliva, cerebrospinal fluid, and pleural effusions, this technique profiles key biomarkers including circulating tumor DNA, circulating tumor cells, microRNAs, and extracellular vesicles. This review discusses the extended scope of liquid biopsy, highlighting its indispensable role in enhancing patient outcomes through early detection, continuous monitoring, and tailored therapy. While the advantages are notable, we also address the challenges, emphasizing the necessity for precision, cost‐effectiveness, and standardized methodologies in its broader application. The future trajectory of liquid biopsy is set to expand its reach in personalized medicine, fueled by technological advancements and collaborative research.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Circulating Tumor DNANeoplastic Cells, CirculatingHumansPrecision MedicineBiomarkers, TumorLiquid Biopsy

Stichwörter der Autor:innen

circulating tumor DNA (ctDNA)liquid biopsynoninvasive cancer detectionpersonalized medicineprecision oncology

Substanzen

Biomarkers, TumorCirculating Tumor DNA

Autor:innen und Institutionen

  • Key Laboratory for Translational Medicine, The First Hospital Affiliated with Huzhou University, Huzhou, China.
  • Department of General Surgery, Puyang Oilfield General Hospital, Puyang, China.
  • Department of Medicine, Moores Cancer Center, and Sanford Stem Cell Institute, University of California San Diego, La Jolla, California, USA.

ORCID-Profile: Wenxue Ma

Zitieren

APA

Bao, Y., Zhang, D., Guo, H., & Ma, W. (2024). Beyond blood: Advancing the frontiers of liquid biopsy in oncology and personalized medicine. Cancer Science, 115(4), 1060-1072. https://doi.org/10.1111/cas.16097

Vancouver

Bao Y, Zhang D, Guo H, Ma W. Beyond blood: Advancing the frontiers of liquid biopsy in oncology and personalized medicine. Cancer Science. 2024;115(4):1060-1072. doi:10.1111/cas.16097

BibTeX
@article{Bao2024,
  author = {Bao, Ying and Zhang, Dejing and Guo, Huihui and Ma, Wenxue},
  title = {Beyond blood: Advancing the frontiers of liquid biopsy in oncology and personalized medicine},
  journal = {Cancer Science},
  year = {2024},
  volume = {115},
  number = {4},
  pages = {1060--1072},
  doi = {10.1111/cas.16097}
}
Kostenlos starten →